Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis
- PMID: 27016052
- PMCID: PMC5036205
- DOI: 10.1136/annrheumdis-2015-208024
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis
Abstract
Objectives: Improvement of skin fibrosis is part of the natural course of diffuse cutaneous systemic sclerosis (dcSSc). Recognising those patients most likely to improve could help tailoring clinical management and cohort enrichment for clinical trials. In this study, we aimed to identify predictors for improvement of skin fibrosis in patients with dcSSc.
Methods: We performed a longitudinal analysis of the European Scleroderma Trials And Research (EUSTAR) registry including patients with dcSSc, fulfilling American College of Rheumatology criteria, baseline modified Rodnan skin score (mRSS) ≥7 and follow-up mRSS at 12±2 months. The primary outcome was skin improvement (decrease in mRSS of >5 points and ≥25%) at 1 year follow-up. A respective increase in mRSS was considered progression. Candidate predictors for skin improvement were selected by expert opinion and logistic regression with bootstrap validation was applied.
Results: From the 919 patients included, 218 (24%) improved and 95 (10%) progressed. Eleven candidate predictors for skin improvement were analysed. The final model identified high baseline mRSS and absence of tendon friction rubs as independent predictors of skin improvement. The baseline mRSS was the strongest predictor of skin improvement, independent of disease duration. An upper threshold between 18 and 25 performed best in enriching for progressors over regressors.
Conclusions: Patients with advanced skin fibrosis at baseline and absence of tendon friction rubs are more likely to regress in the next year than patients with milder skin fibrosis. These evidence-based data can be implemented in clinical trial design to minimise the inclusion of patients who would regress under standard of care.
Keywords: Epidemiology; Outcomes research; Systemic Sclerosis.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Figures

Comment in
-
Predicting improvement in diffuse scleroderma: lessons learnt.Ann Rheum Dis. 2016 Oct;75(10):1741-2. doi: 10.1136/annrheumdis-2016-209116. Epub 2016 May 24. Ann Rheum Dis. 2016. PMID: 27221693 No abstract available.
Similar articles
-
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.Ann Rheum Dis. 2015 Jun;74(6):1124-31. doi: 10.1136/annrheumdis-2014-205226. Epub 2014 Jun 30. Ann Rheum Dis. 2015. PMID: 24981642
-
Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.Ann Rheum Dis. 2019 May;78(5):648-656. doi: 10.1136/annrheumdis-2018-213455. Epub 2019 Mar 9. Ann Rheum Dis. 2019. PMID: 30852552 Free PMC article.
-
Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.Rheumatology (Oxford). 2020 Jul 1;59(7):1715-1724. doi: 10.1093/rheumatology/kez529. Rheumatology (Oxford). 2020. PMID: 31774531
-
Efficacy of cyclophosphamide for skin fibrosis in systemic sclerosis: a systematic review and single-arm meta-analysis.Eur J Clin Pharmacol. 2025 Jun;81(6):863-874. doi: 10.1007/s00228-025-03837-3. Epub 2025 Apr 8. Eur J Clin Pharmacol. 2025. PMID: 40198334
-
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.Arthritis Rheumatol. 2016 Feb;68(2):299-311. doi: 10.1002/art.39501. Arthritis Rheumatol. 2016. PMID: 26808827 Free PMC article. Clinical Trial.
Cited by
-
Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents.Arthritis Res Ther. 2024 Oct 23;26(1):182. doi: 10.1186/s13075-024-03408-4. Arthritis Res Ther. 2024. PMID: 39444017 Free PMC article.
-
Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study.ACR Open Rheumatol. 2020 Aug;2(8):496-502. doi: 10.1002/acr2.11165. Epub 2020 Jul 28. ACR Open Rheumatol. 2020. PMID: 32720753 Free PMC article.
-
High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference.Arthritis Res Ther. 2018 Aug 16;20(1):181. doi: 10.1186/s13075-018-1686-9. Arthritis Res Ther. 2018. PMID: 30115105 Free PMC article.
-
Natural killer cells are decreased in systemic sclerosis and have diagnostic value for pulmonary arterial hypertension incorporation.Sci Rep. 2025 Feb 12;15(1):5178. doi: 10.1038/s41598-025-89238-z. Sci Rep. 2025. PMID: 39939388 Free PMC article.
-
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases.Nat Rev Rheumatol. 2020 Jan;16(1):11-31. doi: 10.1038/s41584-019-0324-5. Epub 2019 Dec 2. Nat Rev Rheumatol. 2020. PMID: 31792399 Free PMC article. Review.